MoonLake Immunotherapeutics
MLTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. At a $1.64B market cap, MoonLake Immunotherapeutics ranks as a small-cap company within healthcare. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Market Cap
$1.64B
Beta
1.04
P/E (TTM)
—
P/E (Fwd)
-5.74
EPS (TTM)
$-4.02
EPS (Fwd)
$-3.43
ROE
-77.8%
ROA
-36.7%
Cash
$357.9M
Total Debt
$100.8M
Free CF
-$135.9M
52W Change
-62.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $357.9M in cash comfortably exceeding the $100.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$135.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -77.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, MLTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MLTX.